General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Novartis(MODEST), Lilly(MODEST), Amgen Inc.(MODEST), Arrowhead(MODEST), Eli Lilly and Company(MODEST), Regeneron(MODEST), CRISPR Therapeutics(MODEST), Precision BioSciences(MODEST), UltraGenyx(MODEST), Eli Lilly and Company(MODEST), Regeneron(MODEST), CRISPR Therapeutics(MODEST), Precision Biosciences(MODEST), UltraGenyx(MODEST), Amgen(MODEST), Avilar Therapeutics(MODEST), Editas(MODEST), Arrowhead(MODEST) EQUITY INTERESTS/STOCK OPTIONS: MediMergent LLC(SIGNIFICANT) OTHER FINANCIAL BENEFIT: Wolters Kluwer(SIGNIFICANT)

View Full Disclosure